Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Moreau, P.; Usmani, S.; van de Donk, N. W. C. J.; Garfall, A.; Delforge, M.; Oriol, A.; Nooka, A.; Rosiñol, L.; Bahlis, N.; Rodriguez-Otero, P.; Martin, T.; Diels, J.; Van Sanden, S.; Pei, L.; Ammann, E.; Kobos, R.; Marshall, A.; Slavcev, M.; Smit, J.; Londhe, A.; Krishnan, A. |
| Abstract Title: | Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) |
| Meeting Title: | 19th International Myeloma Society Annual Meeting (IMS) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. |
| Meeting Dates: | 2022 Aug 25-27 |
| Meeting Location: | Los Angeles, CA |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-08-01 |
| Start Page: | S181 |
| End Page: | S182 |
| Language: | English |
| ACCESSION: | WOS:000895909200319 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(22)00593-6 |
| Notes: | Meeting Abstract: P-263 -- Source: Wos |
